text: IPO FILING - Transkaryotic Therapies Inc . WASHINGTON 1996-08-27 Company Name Transkaryotic Therapies Inc Nasdaq Stock symbol TKTX Estimated price range $ 13 - $ 15 / shr Total shares to be offered 2.5 million Shrs offered by company 2.5 million Shrs outstanding after ipo 16,668,560 Lead Underwriter Morgan Stanley and Co Inc Underwriters over-allotment 375,000 shrs Shares to be purchased by Hoechst Marion Roussel Inc 357,143 Business : developed two proprietary technology platforms , gene activation and gene therapy . Use of Proceeds : Research , preclinical and clinical product development , and general corporate purposes . Financial Data in 000s : 1995 1994 - Revenue $ 15,400 $ 10,000 - Net Income ( loss ) $ 2,074 ( $ 3,422 )